Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.

Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, Schneider B, Pabinger I, Lechner K, Kyrle PA.

Thromb Haemost. 1998 Oct;80(4):566-9.

PMID:
9798970
2.

High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.

Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S.

N Engl J Med. 2000 Aug 17;343(7):457-62.

3.

Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.

Hansson PO, Sörbo J, Eriksson H.

Arch Intern Med. 2000 Mar 27;160(6):769-74.

PMID:
10737276
4.

The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism.

Kyrle PA, Eichinger S.

Wien Klin Wochenschr. 2003 Aug 14;115(13-14):471-4. Review.

PMID:
13677265
5.

The risk of recurrent venous thromboembolism among patients with high factor IX levels.

Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, Schönauer V, Kyrle PA.

J Thromb Haemost. 2003 Jan;1(1):28-32.

6.

Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.

Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W; Warfarin Optimal Duration Italian Trial Investigators.

N Engl J Med. 2001 Jul 19;345(3):165-9.

7.

Recurrent venous thromboembolism in a Spanish population: incidence, risk factors, and management in a hospital setting.

Grau E, Real E, Medrano J, Pastor E, Selfa S.

Thromb Res. 1999 Dec 1;96(5):335-41.

PMID:
10605948
8.

Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial.

den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM.

Blood. 2007 Jan 1;109(1):139-44. Epub 2006 Sep 7.

9.

Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases.

Hainaut P, Jaumotte C, Verhelst D, Wallemacq P, Gala JL, Lavenne E, Heusterspreute M, Zech F, Moriau M.

Thromb Res. 2002 Apr 15;106(2):121-5.

PMID:
12182910
10.

Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: a hospital-based case-control study.

Oger E, Lacut K, Le Gal G, Couturaud F, Abalain JH, Mercier B, Mottier D; EDITH (Etude des Déterminants/Interaction de la THrombose veineuse) Collaborative Study Group.

Thromb Res. 2007;120(2):207-14. Epub 2006 Nov 28.

PMID:
17126889
11.

Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism.

Eichinger S, Weltermann A, Minar E, Stain M, Schönauer V, Schneider B, Kyrle PA.

Arch Intern Med. 2004 Jan 12;164(1):92-6.

PMID:
14718328
12.

Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.

Santamaria MG, Agnelli G, Taliani MR, Prandoni P, Moia M, Bazzan M, Guazzaloca G, Ageno W, Bertoldi A, Silingardi M, Tomasi C, Ambrosio GB; Warfarin Optimal Duration Italian Trial (WODIT) Investigators.

Thromb Res. 2005;116(4):301-6. Epub 2005 Jan 26.

PMID:
16038714
13.

Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism.

Marcucci R, Liotta AA, Cellai AP, Rogolino A, Gori AM, Giusti B, Poli D, Fedi S, Abbate R, Prisco D.

Am J Med. 2003 Dec 1;115(8):601-5.

PMID:
14656611
14.
15.

Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study.

Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE.

Arch Intern Med. 2000 Apr 10;160(7):961-4.

PMID:
10761961
16.

Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.

Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S.

Thromb Haemost. 2002 Jan;87(1):7-12.

PMID:
11848459
17.

Extended oral anticoagulant therapy after a first episode of pulmonary embolism.

Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P; Warfarin Optimal Duration Italian Trial Investigators.

Ann Intern Med. 2003 Jul 1;139(1):19-25.

PMID:
12834314
18.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.

Eichinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA.

Blood. 2004 May 15;103(10):3773-6. Epub 2004 Jan 22.

19.

Familial hyperhomocysteinemia-related cerebral venous sinus thrombosis and pulmonary embolism: a case report.

Shen HC, Lo YK, Li JY, Lai PH.

Acta Neurol Taiwan. 2007 Jun;16(2):98-101.

PMID:
17685134
20.

Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence.

Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S.

J Thromb Haemost. 2005 May;3(5):955-61.

Supplemental Content

Support Center